Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16218975 | 0.87 | ALDH1A1 (0.48) | NFE2L2TRPA1ALDH1A1HPGDALOX12 | |
| SCHEMBL29628296 | 0.85 | NFE2L2 (0.50) | NFE2L2TRPA1ALDH1A1HPGDALOX12 | |
| SCHEMBL1674897 | 0.85 | NFE2L2 (0.50) | NFE2L2TRPA1ALDH1A1HPGDALOX12 | |
| SCHEMBL1286236 | 0.85 | NFE2L2 (0.50) | NFE2L2TRPA1ALDH1A1HPGDALOX12 | |
| Benzene SCHEMBL29196105 | 0.85 | NFE2L2 (0.50) | NFE2L2TRPA1ALDH1A1HPGDALOX12 | |
| SCHEMBL12202183 | 0.85 | ALDH1A1 (0.38) | NFE2L2TRPA1ALDH1A1HPGDALOX12 | |
| SCHEMBL10788528 | 0.84 | ALDH1A1 (0.46) | NFE2L2ALDH1A1HPGDALOX12L3MBTL1 | |
| SCHEMBL9915842 | 0.84 | APP (0.46) | TRPA1ALDH1A1HPGDALOX12L3MBTL1 | |
| SCHEMBL14498387 | 0.84 | CYP19A1 (0.50) | NFE2L2TRPA1ALDH1A1HPGDALOX12 | |
| SCHEMBL10788534 | 0.84 | ALDH1A1 (0.46) | NFE2L2ALDH1A1HPGDALOX12L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105711-A1 | CROSSLINKABLE SUBSTITUTED FLUORENE COMPOUNDS AND CONJUGATED OLIGOMERS OR POLYMERS BASED THEREON | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7893160-B2 | Crosslinkable substituted fluorene compounds and conjugated oligomers or polymers based thereon | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-22 | — | — | US | disclosed |
| US-20080265755-A1 | Biscarbazol-9-Yl-Substituted Triarylamine-Containing Polymers and Electronic Devices | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20070102695-A1 | Crosslinkable substituted fluorene compounds and conjugated oligomers or polymers based thereon | DOW GLOBAL TECHNOLOGIES INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105711-A1 | CROSSLINKABLE SUBSTITUTED FLUORENE COMPOUNDS AND CONJUGATED OLIGOMERS OR POLYMERS BASED THEREON | THEM6, PCNA, PARG | NFE2L2 602/4885TRPA1 1607/4885ALDH1A1 2935/4885 |
| US-20070102695-A1 | Crosslinkable substituted fluorene compounds and conjugated oligomers or polymers based thereon | THEM6, PCNA, PARG | NFE2L2 715/4885TRPA1 1066/4885ALDH1A1 2938/4885 |
| US-20080265755-A1 | Biscarbazol-9-Yl-Substituted Triarylamine-Containing Polymers and Electronic Devices | PYM1, KCNMB4, BRD9 | NFE2L2 3029/4885TRPA1 3229/4885ALDH1A1 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.